A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
Al Olama AA., Kote-Jarai Z., Berndt SI., Conti DV., Schumacher F., Han Y., Benlloch S., Hazelett DJ., Wang Z., Saunders E., Leongamornlert D., Lindstrom S., Jugurnauth-Little S., Dadaev T., Tymrakiewicz M., Stram DO., Rand K., Wan P., Stram A., Sheng X., Pooler LC., Park K., Xia L., Tyrer J., Kolonel LN., Le Marchand L., Hoover RN., Machiela MJ., Yeager M., Burdette L., Chung CC., Hutchinson A., Yu K., Goh C., Ahmed M., Govindasami K., Guy M., Tammela TLJ., Auvinen A., Wahlfors T., Schleutker J., Visakorpi T., Leinonen KA., Xu J., Aly M., Donovan J., Travis RC., Key TJ., Siddiq A., Canzian F., Khaw K-T., Takahashi A., Kubo M., Pharoah P., Pashayan N., Weischer M., Nordestgaard BG., Nielsen SF., Klarskov P., Røder MA., Iversen P., Thibodeau SN., McDonnell SK., Schaid DJ., Stanford JL., Kolb S., Holt S., Knudsen B., Coll AH., Gapstur SM., Diver WR., Stevens VL., Maier C., Luedeke M., Herkommer K., Rinckleb AE., Strom SS., Pettaway C., Yeboah ED., Tettey Y., Biritwum RB., Adjei AA., Tay E., Truelove A., Niwa S., Chokkalingam AP., Cannon-Albright L., Cybulski C., Wokołorczyk D., Kluźniak W., Park J., Sellers T., Lin H-Y., Isaacs WB., Partin AW., Brenner H., Dieffenbach AK., Stegmaier C., Chen C., Giovannucci EL., Ma J., Stampfer M., Penney KL., Mucci L., John EM., Ingles SA., Kittles RA., Murphy AB., Pandha H., Michael A., Kierzek AM., Blot W., Signorello LB., Zheng W., Albanes D., Virtamo J., Weinstein S., Nemesure B., Carpten J., Leske C., Wu S-Y., Hennis A., Kibel AS., Rybicki BA., Neslund-Dudas C., Hsing AW., Chu L., Goodman PJ., Klein EA., Zheng SL., Batra J., Clements J., Spurdle A., Teixeira MR., Paulo P., Maia S., Slavov C., Kaneva R., Mitev V., Witte JS., Casey G., Gillanders EM., Seminara D., Riboli E., Hamdy FC., Coetzee GA., Li Q., Freedman ML., Hunter DJ., Muir K., Gronberg H., Neal DE., Southey M., Giles GG., Severi G., Breast and Prostate Cancer Cohort Consortium (BPC3) None., PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium None., COGS (Collaborative Oncological Gene-environment Study) Consortium None., GAME-ON/ELLIPSE Consortium None., Cook MB., Nakagawa H., Wiklund F., Kraft P., Chanock SJ., Henderson BE., Easton DF., Eeles RA., Haiman CA.
Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of > 10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10(-8); 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.